Andrade-Castellanos CA

Idioma: Español
Referencias bibliográficas: 36
Paginas: 634-641
Archivo PDF: 188.22 Kb.

RESUMEN

La cetoacidosis diabética es un estado metabólico extremo causado por la deficiencia absoluta o relativa de insulina. La enfermedad refleja los efectos de la deficiencia de esta hormona en múltiples tejidos, lo que explica la poliuria, polidipsia, el dolor abdominal y la alteración del nivel de conciencia. La administración intravenosa de líquidos, con posterior aplicación de insulina, constituye la piedra angular del tratamiento. Este trabajo pretende ser una revisión actualizada del manejo de esta complicación aguda de la diabetes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Andrade-Castellanos CA, Colunga-Lozano LE. Systematicreview with meta-analysis: Subcutaneous insulin glarginecoadministration for diabetic ketoacidosis. Gac Med Mex. 2016;152:761-769.

2. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN, et al. Hyperglycemiccrises in adult patients with diabetes. DiabetesCare 2009; 32: 1335-1343. doi: 10.2337/dc09-9032.

3. Chua HR, Schneider A, Bellomo R. Bicarbonate in diabeticketoacidosis - a systematic review. Ann Intensive Care 2011;1 (1): 23. doi: 10.1186/2110-5820-1-23.

4. Oh MS, Banerji MA, Carroll HJ. The mechanism of hyperchloremicacidosis during the recovery phase of diabeticketoacidosis. Diabetes 1981; 30: 310-313. doi: 10.2337/diab.30.4.310.

5. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, et al. Balancedcrystalloids versus saline in critically ill adults. N EnglJ Med 2018; 378: 829-839. DOI: 10.1056/NEJMoa1711584.

6. Yunos NM, Bellomo R, Hegarty C, Story D, et al. Associationbetween a chloride-liberal vs chloride-restrictive intravenousfluid administration strategy and kidney injury in criticallyill adults. JAMA 2012; 308: 1566-1572. doi:10.1001/jama.2012.13356.

7. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized,controlled, double-blind crossover study on the effects of2-L infusions of 0.9% saline and plasma-lyte® 148 on renalblood flow velocity and renal cortical tissue perfusionin healthy volunteers. Ann Surg 2012; 256: 18-24. doi:10.1097/SLA.0b013e318256be72.

8. Mahler SA, Conrad SA, Wang H, et al. Resuscitation withbalanced electrolyte solution prevents hyperchloremicmetabolic acidosis in patients with diabetic ketoacidosis.Am J Emerg Med 2011; 29 (6): 670-674. doi: 10.1016/j.ajem.2010.02.004.

9. Van Zyl DG, Rheeder P, Delport E. Fluid management indiabetic-acidosis--Ringer's lactate versus normal saline: arandomized controlled trial. QJM 2012; 105 (4): 337-343.doi: 10.1093/qjmed/hcr226.

10. Yung M, Letton G, Keeley S. Controlled trial of Hartmann’ssolution versus 0.9% saline for diabetic ketoacidosis. JPaediatr Child Health 2017; 53 (1): 12-17. doi: 10.1111/jpc.13436.

11. Aditianingsih D, Djaja AS, George YWH. The effect ofbalanced electrolyte solution versus normal saline in theprevention of hyperchloremic metabolic acidosis in diabeticketoacidosis patients: a randomized controlled trial. MedJ Indones 2017; 26: 134-140. https://doi.org/10.13181/mji.v26i2.1542.

12. Gunnerson KJ, Saul M, He S, Kellum JA. Lactate versusnon-lactate metabolic acidosis: a retrospective outcomeevaluation of critically ill patients. Crit Care 2006; 10 (1):R22. doi: 10.1186/cc3987.

13. Mathes DD, Morell RC, Rohr MS. Dilutional acidosis: is it areal clinical entity? Anesthesiology 1997; 86 (2): 501-503.https://doi.org/10.1097/00000542-199702000-00028.

14. Doberer D, Funk GC, Schneeweiss B. Dilutional acidosis:an endless story of confusion. Crit Care Med 2003; 31(1): 337-338. doi: 10.1097/00003246-200301000-00073.

15. Long B, Koyfman A. Emergency medicine myths: cerebraledema in pediatric diabetic ketoacidosis and intravenousfluids. J Emerg Med 2017; 53 (2): 212-221. doi: 10.1016/j.jemermed.2017.03.014.

16. Kuppermann N, Ghetti S, Schunk JE, Stoner MJ, RewersA, McManemy JK, et al. Clinical trial of fluid infusion ratesfor pediatric diabetic ketoacidosis. N Engl J Med 2018; 378(24): 2275-2287. DOI: 10.1056/NEJMoa1716816.

17. Couch RM, Acott PD, Wong GW. Early onset fatal cerebraledema in diabetic ketoacidosis. Diabetes Care 1991; 14(1): 78-79. doi: 10.2337/diacare.14.1.78b.

18. Glaser NS, Wootton-Gorges SL, Marcin JP, Buonocore MH,Dicarlo J, Neely EK, et al. Mechanism of cerebral edema inchildren with diabetic ketoacidosis. J Pediatr 2004; 145 (2):164-171. doi: 10.1016/j.jpeds.2004.03.045.

19. Banting FG, Best CH, Collip JB, Campbell WR, Flecher AA.Pancreatic extracts in the treatment of diabetes mellitus.CMAJ 1922; 12: 141-146.

20. Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospitaladmission for diabetic ketoacidosis in adults with type 1and type 2 diabetes in England, 1998-2013: A retrospectivecohort study. Diabetes Care 2018; 41 (9): 1870-1877. doi:10.2337/dc17-1583.

21. Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis:A review. Curr Diabetes Rev 2017; 13 (3): 315-321.doi: 10.2174/1573399812666160421121307.

22. Savage MW, Dhatariya KK, Kilvert A, Rayman G, ReesJA, Courtney CH, et al. Joint British Diabetes Societiesguideline for the management of diabetic ketoacidosis.Diabet Med 2011; 28 (5): 508-515. doi: 10.1111/j.1464-5491.2011.03246.x.

23. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-FigueroaN, Gonzalez-Padilla DA. Subcutaneous rapid-actinginsulin analogues for diabetic ketoacidosis. Cochrane DatabaseSyst Rev 2016; (1): CD011281. doi: 10.1002/14651858.CD011281.pub2.

24. Houshyar J, Bahrami A, Aliasgarzadeh A. Effectiveness ofinsulin glargine on recovery of patients with diabetic ketoacidosis: a randomized controlled trial. J Clin Diagn Res2015; 9: OC01-5. doi: 10.7860/JCDR/2015/12005.5883.

25. Czosnowski QA, Swanson JM, Lobo BL, Broyles JE, DeatonPR, Finch CK. Evaluation of glycemic control following discontinuationof an intensive insulin protocol. J Hosp Med2009; 4: 28-34. doi: 10.1002/jhm.393.

26. Greenhalgh T. Assessing the methodological quality ofpublished papers. BMJ 1997; 315 (7103): 305-308. doi:10.1136/bmj.315.7103.305.

27. Adrogué HJ, Madias NE. Management of life-threateningacid-base disorders. N Engl J Med 1998; 338 (1): 26-34.DOI: 10.1056/NEJM199801013380106.

28. Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonatein the treatment of diabetic ketoacidosis. Br Med Bull1984; 289: 1035-1038. doi: 10.1136/bmj.289.6451.1035.

29. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapyin severe diabetic ketoacidosis. Ann Intern Med 1986; 105(6): 836-840. doi: 10.7326/0003-4819-105-6-836.

30. Gamba G, Oseguera J, Castrejon M, Gomez-Perez FJ. Bicarbonatetherapy in severe diabetic ketoacidosis. A doubleblind, randomized, placebo controlled trial. Rev Invest Clin1991; 43: 234-238.

31. Adrogué HJ, Barrero J, Eknoyan G. Salutary effects ofmodest fluid replacement in the treatment of adults withdiabetic ketoacidosis. Use in patients without extremevolume deficit. JAMA 1989; 262 (15): 2108-2113. doi:10.1001/jama.1989.03430150076029.

32. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL,Charytan DM, et al. Canagliflozin and renal outcomes intype 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-2306. DOI: 10.1056/NEJMoa1811744.

33. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, HirschIB. Euglycemic diabetic ketoacidosis: a potential complicationof treatment with sodium-glucose cotransporter2 inhibition. Diabetes Care 2015; 38 (9): 1687-1693. doi:10.2337/dc15-0843.

34. Liu J, Li L, Li S, Wang Y, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patientswith type 2 diabetes: A systematic review and metaanalysisof randomized controlled trials. Diabetes ObesMetab 2020; 22 (9): 1619-1627. doi:10.1111/dom.14075.

35. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirusto its receptor damages islets and causes acute diabetes.Acta Diabetol 2010; 47 (3): 193‐199. doi:10.1007/s00592-009-0109-4.

36. Rayman G, Lumb A, Kennon B, et al. Guidance on themanagement of diabetic ketoacidosis in the exceptionalcircumstances of the COVID-19 pandemic. Diabet Med2020; 37 (7): 1214-1216. doi:10.1111/dme.14328.